AGN up +0.12% percent Today $AGN High is at 196.70
Post# of 58
Posted On: 11/11/2014 4:03:25 PM
AGN up +0.12% percent Today $AGN High is at 196.70 and the Low 194.81 with current volume of 631,266.
Recent News posted below.
Allergan Inc AGN other info.
http://investorshangout.com/Allergan-AGN-50031/
AGN Allergan Inc Recent Headline News
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.99 (-0.13), AGN: 195.47 (+0.23), ACT: 243.86 (-1.87), VRX: 129.67 (+1.68), MDT: 69.00 (+0.29), SLXP: 99.88 (+6.01), SNY: 47.11 (+0.92)
New Survey Reveals What Women in the U.S. Really Want to Know About BOTOX® Cosmetic (onabotulinumtoxinA)
PR Newswire - Tue Nov 11, 7:47AM CST
Many women are familiar with the brand name BOTOX® Cosmetic (onabotulinumtoxinA), but a new study from SheSpeaks(TM), an online community of women, reveals what they really want to know about it.1 To address the most common questions women have - and there are nearly 10 million women who are considering treatment2 - Allergan, Inc., maker of BOTOX® Cosmetic, teamed up with SheSpeaks to identify these questions and provide answers.
AGN: 195.47 (+0.23)
Merck Reports Interim Data on Hepatitis C Virus Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 3:45PM CST
Merck (MRK) presented interim data from a proof-of-concept study on its fixed-dose combination regimen - grazoprevir/elbasvir - in combination with Gilead's Sovaldi.
AGN: 195.47 (+0.23), GILD: 108.10 (+1.08), MRK: 59.45 (+0.64), ABBV: 63.76 (-0.03)
Salix Crashes on Inventory Issues, Lowered Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Nov 10, 1:56PM CST
Salix's (SLXP) wholesale inventory levels for its products were much higher than previously announced.
AGN: 195.47 (+0.23), VRX: 129.67 (+1.68), AUXL: 32.63 (-0.07), SLXP: 99.88 (+6.01)
Emergent BioSolutions Beats on Q3 Earnings, Guidance Up - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Mon Nov 10, 11:30AM CST
Emergent BioSolutions reported third quarter earnings of 67 cents per share.
AGN: 195.47 (+0.23), EBS: 24.39 (+0.44), ABAX: 53.98 (+1.04), ABBV: 63.76 (-0.03)
Gilead (GILD) Submits HIV Combination Drug for FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 5:50PM CST
Gilead Sciences, Inc. announced that it has submitted a New Drug Application to the FDA for its tenofovir alafenamide-based single tablet regimen.
AGN: 195.47 (+0.23), JNJ: 108.85 (+0.03), GILD: 108.10 (+1.08), ABBV: 63.76 (-0.03)
Novartis' (NVS) LBH589 Gets Unfavorable FDA Panel Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:20PM CST
Novartis (NVS) received disappointing news when the FDA's Oncologic Drugs Advisory Committee (ODAC) did not recommend its pipeline candidate LBH589.
AGN: 195.47 (+0.23), ABBV: 63.76 (-0.03), BMY: 58.66 (-0.15), NVS: 92.77 (+0.14)
Stock Movers: Why These 4 Medical Stocks Dived Today
at Investor's Business Daily - Fri Nov 07, 3:36PM CST
Raised eyebrows can lead to declining stock prices. Stocks On The Move down today include Salix Pharmaceuticals (SLXP), embroiled in drama as questions of accuracy and honesty cloud the drugmaker's weak Q3 results. Are its inventories accurate, and...
AGN: 195.47 (+0.23), VRX: 129.70 (+1.71), DVA: 76.01 (+1.29), GILD: 108.10 (+1.08), SLXP: 99.88 (+6.01), ICPT: 172.42 (-3.93), HUM: 136.49 (+4.03)
Ride The Smart-Money Coattails: Use IBD's Funds Pages
at Investor's Business Daily - Fri Nov 07, 3:10PM CST
Selecting stocks that have superior profit and sales growth is not the sole key to success in the market. Neither is simply buying stocks with outstanding price strength. Before you invest in a stock, make sure that it also is a favorite among the...
AGN: 195.47 (+0.23), HCA: 66.27 (+0.52), BIDU: 249.94 (+2.36), ZBRA: 72.25 (-0.73), SWKS: 60.92 (-0.05), ALK: 56.15 (-0.17), CELG: 107.73 (-0.28)
AstraZeneca (AZN) Misses on Q3 Earnings, Raises Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:20PM CST
AstraZeneca (AZN) reported third-quarter 2014 core earnings of $1.05 per ADS that missed the Zacks Consensus Estimate by a penny.
AGN: 195.47 (+0.23), AZN: 74.26 (+1.05), ABBV: 63.76 (-0.03), AEGR: 21.62 (+0.05)
These Six Stocks Are Driving Bill Ackman's Extraordinary 2014 Run
at The Street - Fri Nov 07, 12:01PM CST
It's been a banner year for billionaire hedge fund magnate Bill Ackman -- especially considering just a handful of companies are propelling his big 2014 run.
AGN: 195.47 (+0.23), VRX: 129.70 (+1.71), HHC: 147.22 (+1.83), PAH: 25.02 (-0.38), CP: 209.92 (+0.99), APD: 134.80 (-0.10), BKW: 32.55 (+0.14)
Salix Q3 Earnings Marred by Inventory Issues, Cuts View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Nov 07, 10:09AM CST
Salix's (SLXP) Audit Committee has appointed outside counsel to probe the inventory issues.
AGN: 195.47 (+0.23), BIIB: 324.13 (-3.74), AUXL: 32.63 (-0.07), SLXP: 99.88 (+6.01)
Cramer: Salix Pharmaceuticals' Audit Committee Review Is Concerning
at The Street - Fri Nov 07, 9:54AM CST
TheStreet's Jim Cramer takes a look at Salix Pharmaceuticals, whose stock is plunging after the company announced a slew of bad news.
AGN: 195.47 (+0.23), SLXP: 99.88 (+6.01)
SurModics Beats on Q4 Earnings, Issues Fiscal 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:10AM CST
SurModics, Inc.???s fourth-quarter fiscal 2014 adjusted earnings of 26 cents per share beat the Zacks Consensus Estimate by a penny.
AGN: 195.47 (+0.23), SRDX: 21.31 (+0.45), ABAX: 53.98 (+1.04), ABBV: 63.77 (-0.02)
Wall Street Breakfast: Home Depot Says 53M Emails Stolen During Breach
Wall Street Breakfast - Seeking Alpha - Fri Nov 07, 5:30AM CST
Economy German industrial production fell short of the consensus forecast of a 2% rise in September, signaling that Europe’s largest economy is struggling to recover. Output rose 1.4% from August, when it contracted a revised 3.1%, the...
ACAS: 15.54 (+0.03), NKE: 94.85 (-0.11), PEP: 96.79 (-0.18), AGN: 195.47 (+0.23), VLO: 51.09 (+0.50), PBR: 10.65 (+0.03), SPY: 204.07 (+0.09), TGT: 65.76 (+0.24), BP: 41.77 (-0.09), HMC: 31.03 (-0.52), APC: 92.98 (+0.64), RAI: 65.11 (-0.36), AMZN: 312.15 (+7.04), PSX: 73.50 (-1.00), HD: 98.12 (-0.04), PBF: 26.57 (+0.68), SLXP: 99.88 (+6.01), BAC: 17.33 (-0.04), BKS: 22.53 (+0.03), AVG: 19.48 (-0.11), CALM: 42.68 (+0.24), QQQ: 102.21 (+0.25), TSO: 72.58 (+1.15), MPC: 94.64 (+0.54), CVX: 118.40 (+0.48)
Ad hoc: Biofrontera to take over the sales and marketing of Ameluz(R) in Spain from Allergan
Thomson Reuters ONE - Fri Nov 07, 2:20AM CST
Biofrontera AG / Keyword(s): Misc. matters / Ad hoc: Biofrontera to take over the sales and marketing of Ameluz(R) in Spain from Allergan . Ad hoc announcement according to 15 WpHG. Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
AGN: 195.47 (+0.23)
Salix shares plummet, CFO resigns
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 12:53AM CST
AGN: 195.47 (+0.23), SLXP: 99.88 (+6.01)
Hospira Beats on Earnings & Sales in Q3, Narrows Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:53PM CST
Hospira reported third-quarter 2014 adjusted earnings of 74 cents per share.
AGN: 195.47 (+0.23), ABAX: 53.98 (+1.04), ABBV: 63.77 (-0.02), HSP: 57.41 (+1.43)
Stocks On Indefinite Tack; Rumors See Actavis Merger
at Investor's Business Daily - Thu Nov 06, 11:05AM CST
Stock indexes moved in an indefinite fashion midday Thursday despite speculation that the European Central Bank is moving closer to quantitative easing. The Nasdaq and the S&P 500 shifted 0.1% up and 0.1% down, unable to find traction in either...
AGN: 195.47 (+0.23), ACT: 243.86 (-1.87), MSFT: 48.80 (-0.09), VZ: 50.57 (-0.15)
Perrigo Misses on Earnings and Sales, Maintains Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 10:08AM CST
Perrigo Companys reported first-quarter fiscal 2015 earnings of $1.40 per share.
AGN: 195.47 (+0.23), BIIB: 324.13 (-3.74), PRGO: 155.39 (-1.17), ABBV: 63.77 (-0.02)
Recent News posted below.
Allergan Inc AGN other info.
http://investorshangout.com/Allergan-AGN-50031/
AGN Allergan Inc Recent Headline News
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 23.99 (-0.13), AGN: 195.47 (+0.23), ACT: 243.86 (-1.87), VRX: 129.67 (+1.68), MDT: 69.00 (+0.29), SLXP: 99.88 (+6.01), SNY: 47.11 (+0.92)
New Survey Reveals What Women in the U.S. Really Want to Know About BOTOX® Cosmetic (onabotulinumtoxinA)
PR Newswire - Tue Nov 11, 7:47AM CST
Many women are familiar with the brand name BOTOX® Cosmetic (onabotulinumtoxinA), but a new study from SheSpeaks(TM), an online community of women, reveals what they really want to know about it.1 To address the most common questions women have - and there are nearly 10 million women who are considering treatment2 - Allergan, Inc., maker of BOTOX® Cosmetic, teamed up with SheSpeaks to identify these questions and provide answers.
AGN: 195.47 (+0.23)
Merck Reports Interim Data on Hepatitis C Virus Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 3:45PM CST
Merck (MRK) presented interim data from a proof-of-concept study on its fixed-dose combination regimen - grazoprevir/elbasvir - in combination with Gilead's Sovaldi.
AGN: 195.47 (+0.23), GILD: 108.10 (+1.08), MRK: 59.45 (+0.64), ABBV: 63.76 (-0.03)
Salix Crashes on Inventory Issues, Lowered Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Nov 10, 1:56PM CST
Salix's (SLXP) wholesale inventory levels for its products were much higher than previously announced.
AGN: 195.47 (+0.23), VRX: 129.67 (+1.68), AUXL: 32.63 (-0.07), SLXP: 99.88 (+6.01)
Emergent BioSolutions Beats on Q3 Earnings, Guidance Up - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Mon Nov 10, 11:30AM CST
Emergent BioSolutions reported third quarter earnings of 67 cents per share.
AGN: 195.47 (+0.23), EBS: 24.39 (+0.44), ABAX: 53.98 (+1.04), ABBV: 63.76 (-0.03)
Gilead (GILD) Submits HIV Combination Drug for FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 5:50PM CST
Gilead Sciences, Inc. announced that it has submitted a New Drug Application to the FDA for its tenofovir alafenamide-based single tablet regimen.
AGN: 195.47 (+0.23), JNJ: 108.85 (+0.03), GILD: 108.10 (+1.08), ABBV: 63.76 (-0.03)
Novartis' (NVS) LBH589 Gets Unfavorable FDA Panel Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:20PM CST
Novartis (NVS) received disappointing news when the FDA's Oncologic Drugs Advisory Committee (ODAC) did not recommend its pipeline candidate LBH589.
AGN: 195.47 (+0.23), ABBV: 63.76 (-0.03), BMY: 58.66 (-0.15), NVS: 92.77 (+0.14)
Stock Movers: Why These 4 Medical Stocks Dived Today
at Investor's Business Daily - Fri Nov 07, 3:36PM CST
Raised eyebrows can lead to declining stock prices. Stocks On The Move down today include Salix Pharmaceuticals (SLXP), embroiled in drama as questions of accuracy and honesty cloud the drugmaker's weak Q3 results. Are its inventories accurate, and...
AGN: 195.47 (+0.23), VRX: 129.70 (+1.71), DVA: 76.01 (+1.29), GILD: 108.10 (+1.08), SLXP: 99.88 (+6.01), ICPT: 172.42 (-3.93), HUM: 136.49 (+4.03)
Ride The Smart-Money Coattails: Use IBD's Funds Pages
at Investor's Business Daily - Fri Nov 07, 3:10PM CST
Selecting stocks that have superior profit and sales growth is not the sole key to success in the market. Neither is simply buying stocks with outstanding price strength. Before you invest in a stock, make sure that it also is a favorite among the...
AGN: 195.47 (+0.23), HCA: 66.27 (+0.52), BIDU: 249.94 (+2.36), ZBRA: 72.25 (-0.73), SWKS: 60.92 (-0.05), ALK: 56.15 (-0.17), CELG: 107.73 (-0.28)
AstraZeneca (AZN) Misses on Q3 Earnings, Raises Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:20PM CST
AstraZeneca (AZN) reported third-quarter 2014 core earnings of $1.05 per ADS that missed the Zacks Consensus Estimate by a penny.
AGN: 195.47 (+0.23), AZN: 74.26 (+1.05), ABBV: 63.76 (-0.03), AEGR: 21.62 (+0.05)
These Six Stocks Are Driving Bill Ackman's Extraordinary 2014 Run
at The Street - Fri Nov 07, 12:01PM CST
It's been a banner year for billionaire hedge fund magnate Bill Ackman -- especially considering just a handful of companies are propelling his big 2014 run.
AGN: 195.47 (+0.23), VRX: 129.70 (+1.71), HHC: 147.22 (+1.83), PAH: 25.02 (-0.38), CP: 209.92 (+0.99), APD: 134.80 (-0.10), BKW: 32.55 (+0.14)
Salix Q3 Earnings Marred by Inventory Issues, Cuts View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Nov 07, 10:09AM CST
Salix's (SLXP) Audit Committee has appointed outside counsel to probe the inventory issues.
AGN: 195.47 (+0.23), BIIB: 324.13 (-3.74), AUXL: 32.63 (-0.07), SLXP: 99.88 (+6.01)
Cramer: Salix Pharmaceuticals' Audit Committee Review Is Concerning
at The Street - Fri Nov 07, 9:54AM CST
TheStreet's Jim Cramer takes a look at Salix Pharmaceuticals, whose stock is plunging after the company announced a slew of bad news.
AGN: 195.47 (+0.23), SLXP: 99.88 (+6.01)
SurModics Beats on Q4 Earnings, Issues Fiscal 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:10AM CST
SurModics, Inc.???s fourth-quarter fiscal 2014 adjusted earnings of 26 cents per share beat the Zacks Consensus Estimate by a penny.
AGN: 195.47 (+0.23), SRDX: 21.31 (+0.45), ABAX: 53.98 (+1.04), ABBV: 63.77 (-0.02)
Wall Street Breakfast: Home Depot Says 53M Emails Stolen During Breach
Wall Street Breakfast - Seeking Alpha - Fri Nov 07, 5:30AM CST
Economy German industrial production fell short of the consensus forecast of a 2% rise in September, signaling that Europe’s largest economy is struggling to recover. Output rose 1.4% from August, when it contracted a revised 3.1%, the...
ACAS: 15.54 (+0.03), NKE: 94.85 (-0.11), PEP: 96.79 (-0.18), AGN: 195.47 (+0.23), VLO: 51.09 (+0.50), PBR: 10.65 (+0.03), SPY: 204.07 (+0.09), TGT: 65.76 (+0.24), BP: 41.77 (-0.09), HMC: 31.03 (-0.52), APC: 92.98 (+0.64), RAI: 65.11 (-0.36), AMZN: 312.15 (+7.04), PSX: 73.50 (-1.00), HD: 98.12 (-0.04), PBF: 26.57 (+0.68), SLXP: 99.88 (+6.01), BAC: 17.33 (-0.04), BKS: 22.53 (+0.03), AVG: 19.48 (-0.11), CALM: 42.68 (+0.24), QQQ: 102.21 (+0.25), TSO: 72.58 (+1.15), MPC: 94.64 (+0.54), CVX: 118.40 (+0.48)
Ad hoc: Biofrontera to take over the sales and marketing of Ameluz(R) in Spain from Allergan
Thomson Reuters ONE - Fri Nov 07, 2:20AM CST
Biofrontera AG / Keyword(s): Misc. matters / Ad hoc: Biofrontera to take over the sales and marketing of Ameluz(R) in Spain from Allergan . Ad hoc announcement according to 15 WpHG. Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
AGN: 195.47 (+0.23)
Salix shares plummet, CFO resigns
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 12:53AM CST
AGN: 195.47 (+0.23), SLXP: 99.88 (+6.01)
Hospira Beats on Earnings & Sales in Q3, Narrows Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:53PM CST
Hospira reported third-quarter 2014 adjusted earnings of 74 cents per share.
AGN: 195.47 (+0.23), ABAX: 53.98 (+1.04), ABBV: 63.77 (-0.02), HSP: 57.41 (+1.43)
Stocks On Indefinite Tack; Rumors See Actavis Merger
at Investor's Business Daily - Thu Nov 06, 11:05AM CST
Stock indexes moved in an indefinite fashion midday Thursday despite speculation that the European Central Bank is moving closer to quantitative easing. The Nasdaq and the S&P 500 shifted 0.1% up and 0.1% down, unable to find traction in either...
AGN: 195.47 (+0.23), ACT: 243.86 (-1.87), MSFT: 48.80 (-0.09), VZ: 50.57 (-0.15)
Perrigo Misses on Earnings and Sales, Maintains Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 10:08AM CST
Perrigo Companys reported first-quarter fiscal 2015 earnings of $1.40 per share.
AGN: 195.47 (+0.23), BIIB: 324.13 (-3.74), PRGO: 155.39 (-1.17), ABBV: 63.77 (-0.02)
(0)
(0)